Outcome and management of rare high-grade “salivary” adenocarcinoma: the important role of adjuvant (chemo)radiotherapy

Scherl C, Haderlein M, Agaimy A, Mantsopoulos K, Koch M, Traxdorf M, Fietkau R, Grundtner P, Iro H (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Strahlentherapie und Onkologie Urban & Vogel

Abstract

Purpose: To determine survival and management strategies for high-grade adenocarcinoma of salivary glands (ASG). Methods: A retrospective analysis of cases diagnosed between 1998 and 2015 from our single tertiary referral center was performed. Multivariable logistic regression was used to determine factors associated with survival. Results: Thirty-eight cases of high-grade ASG were identified. Most patients were men (68.4%) with a median age of 65.5 years (range 23–84 years). Most tumors were T3 and T4 (65.8%). Regional metastases were common (55.2%), and 42.1% developed distant metastases. The mean follow-up was 60.5 months. All patients received surgery as primary treatment, with 84.2% of patients receiving adjuvant radiation therapy or chemoradiotherapy ([C]RT). Cumulative overall survival was 89.1%, 50.9%, and 20.7% after 1, 5, and 10 years, respectively. Disease-specific survival was 94.4%, 69.8%, and 42.8%, and distant-metastases-free survival (DMFS) was 80.5%, 50.1%, and 40.1% after 1, 5, and 10 years. On multivariable analysis, advanced T status correlated with DMFS (hazard ratio 2.75, 95% CI 0.93–8.16). Postsurgical (C)RT reduced the locoregional recurrence rate by 23.9%, and it improved the locoregional-recurrence-free survival by 39% (p = 0.094). Conclusion: High-grade ASG is considered to have an unfavorable prognosis. Adjuvant (C)RT reduces the rate of locoregional recurrences. Distant metastases are common, and an advanced T stage has increased prognostic value for development of early distant lesions.

Authors with CRIS profile

Marlen Haderlein Department of Radiation Oncology Abbas Agaimy Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Konstantinos Mantsopoulos Department of Otorhinolaryngology – Head and Neck Surgery Maximilian Traxdorf Lehrstuhl für Hals-, Nasen- und Ohrenheilkunde Rainer Fietkau Lehrstuhl für Strahlentherapie Heinrich Iro Lehrstuhl für Hals-, Nasen- und Ohrenheilkunde

How to cite

APA:

Scherl, C., Haderlein, M., Agaimy, A., Mantsopoulos, K., Koch, M., Traxdorf, M.,... Iro, H. (2019). Outcome and management of rare high-grade “salivary” adenocarcinoma: the important role of adjuvant (chemo)radiotherapy. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-019-01499-6

MLA:

Scherl, Claudia, et al. "Outcome and management of rare high-grade “salivary” adenocarcinoma: the important role of adjuvant (chemo)radiotherapy." Strahlentherapie und Onkologie (2019).

BibTeX: Download